While the neovascular form of late AMD has been treatable for nearly 2 decades with intravitreal anti-VEGF injections [3–6], the first treatment options for the atrophic form of late AMD have only recently been approved by the Food and Drug Administration (FDA). Here, VEGFA is linked to age-related macular degeneration.